Cumberland Pharma: Caldolor Shows Reduction Of Opioid Use In Orthopedic Trauma Patients

(RTTNews) - Cumberland Pharmaceuticals Inc. (CPIX) said that a single-center, randomized, double-blind, placebo-controlled study results demonstrated that Caldolor Injection significantly reduces the quantity of opioids required to manage pain after a traumatic injury with fracture.

In addition, the time to first narcotic medication was longer in the Caldolor group than with hospital standard of care. Further, pain was managed better in the Caldolor group compared to standard of care narcotics.

In Monday pre-market trade, CPIX is currently trading at $4.36 up $1.07 or 32.52 percent.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More